ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Opportunity lost

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Jan 14, 2022 12:41pm

82 Views

Post# 34317571

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Opportunity lost

Thanks Mole,
With my limited knowledge on stock trading, I still can't fathom how anyone can possibly short a penny stock (especially at this share price) unless it's someone in the know and when the company is arguably sitting in the best position in its history and on the cusp of something big if you were to believe the CEO's recent declarations.

Any thoughts anyone?

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing